Alan Lewis of the Juvenile Diabetes Research Foundation distinguishes type 1 and type 2 diabetes, and continues to explain how stem cells are being used today to develop new treatments for type 1 diabetes (a.k.a. juvenile diabetes). Human embryonic stem cells (hESC) are being differentiated to the beta (insulin producing) cells that type 1 diabetics lack, and are being transplanted , in animal models. Since type 1 diabetes is an auto-immune disease, the transplanted cells must be protect from destruction by the immune system. Currently, researchers are working towards that goal with encapsulating technologies and a “gentle” immuno-modulation. In order to treat a diabetic patient, access to an unlimited number of cells is necessary. Alan compares embryonic stem cells, adult stem cells, and iPS as source of cells. And finally, in a future outlook, Alan comments on the FDA’s concern for safety, the risk of creating a tumor, artificial pancreas (as an alternative approach), and cell therapy’s potential to CURE diseases
from http://biobusiness.tv/videos/223
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_c.png?x-id=b585b755-7fa4-40ba-b665-73f7527ff047)
Maybe you can find something interesting in the following sponsored links:
FYI
Diabetes and stem cells – http://repairstemcell.wordpress.com/2009/10/02/diabetes-stem-cells-a-brief-history/